BioNeutra Global Corporation
BGACF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $3,050 | $2,650 | $2,458 | $2,701 |
| % Growth | 15.1% | 7.8% | -9% | – |
| Cost of Goods Sold | $2,209 | $1,830 | $2,503 | $1,041 |
| Gross Profit | $841 | $820 | -$46 | $1,659 |
| % Margin | 27.6% | 30.9% | -1.9% | 61.4% |
| R&D Expenses | $24 | $20 | $33 | $26 |
| G&A Expenses | $909 | $1,487 | $948 | $1,088 |
| SG&A Expenses | $952 | $1,523 | $1,068 | $1,162 |
| Sales & Mktg Exp. | $43 | $36 | $120 | $74 |
| Other Operating Expenses | $147 | $135 | $72 | -$174 |
| Operating Expenses | $1,123 | $1,678 | $1,173 | $1,015 |
| Operating Income | -$282 | -$858 | -$655 | $1,458 |
| % Margin | -9.2% | -32.4% | -26.6% | 54% |
| Other Income/Exp. Net | -$130 | $101 | -$178 | $325 |
| Pre-Tax Income | -$412 | -$757 | -$833 | $1,392 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$412 | -$757 | -$833 | $1,392 |
| % Margin | -13.5% | -28.6% | -33.9% | 51.5% |
| EPS | -0.01 | -0.02 | -0.018 | 0.03 |
| % Growth | 50% | -11.7% | -159.7% | – |
| EPS Diluted | -0.01 | -0.016 | -0.018 | 0.03 |
| Weighted Avg Shares Out | 41,224 | 46,449 | 46,449 | 46,449 |
| Weighted Avg Shares Out Dil | 46,449 | 46,449 | 46,449 | 46,449 |
| Supplemental Information | – | – | – | – |
| Interest Income | $80 | $0 | $32 | $103 |
| Interest Expense | $197 | $203 | $206 | $179 |
| Depreciation & Amortization | -$277 | $209 | $221 | $304 |
| EBITDA | -$161 | -$345 | -$405 | $1,875 |
| % Margin | -5.3% | -13% | -16.5% | 69.4% |